Skip to main content
. 2017 Dec 30;168(3):639–647. doi: 10.1007/s10549-017-4616-7

Fig. 1.

Fig. 1

Antitumor activity of alisertib and fulvestrant in a patient with prior progression during five different lines of endocrine therapy for metastatic disease, including tamoxifen, letrozole, fulvestrant, exemestane plus everolimus, and Z-endoxifen (on phase I trial): a baseline before starting alisertib and fulvestrant, and b after 2 cycles of treatment